Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Phase 1TerminatedNCT04764851

Emalex Biosciences Inc.30 enrolled

Overview

This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.

Following a screening period of up to 28 days, subjects will be admitted to the clinical research unit into one of three cohorts. On the morning of Day 1, subjects in cohorts 1, 2, and 3 will receive fasted doses of probe substrate(s) per assigned cohort. On Day 5, Cohort 2 only will receive a second fasted dose of probe substrates. Subjects in cohorts 1, 2, and 3 will receive the final fasted dose of probe substrate(s) on Day 13. Fasted ecopipam administration will begin on Day 5 and will continue through Day 17 at \~2mg/kg for all cohorts. Ecopipam doses will be tapered starting on Day 18 by 25 mg/day increments until subjects are off drug, with final discharge occurring 24 hours after the ecopipam HCl dose has been reduced to 25 mg (Day 21, 23, or 25).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Drug-Interactions

Interventions

ecopipam HCl ~2mg/kg/dayDRUG

oral tablet

Cohort 1 Probe CocktailCOMBINATION_PRODUCT

dextromethorphan, caffeine, omeprazole, and midazolam

Cohort 2 Probe CocktailCOMBINATION_PRODUCT

dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male subjects or female subjects of non-childbearing potential * ≥18 and \<55 years of age at the time of consent * BMI \>18.5 and \<30 kg/m2 and a weight of ≥50 kg for males or ≥45 kg for females * Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug * Male subjects must be willing not to donate sperm until 90 days following the last study drug administration Exclusion Criteria: * Personal or family History of significant medical illness * Clinically significant abnormalities on screening tests/exams * History of or significant risk of committing suicide * Donation of plasma within 7 days prior to dosing * Donation or significant loss of blood within 30 days prior to the first dosing * Major surgery within 3 months or minor surgery within 1 month prior to admission * Use of prohibited prescription, over-the-counter medications or natural health products * Alcohol-based products 24 hours prior to admission * Female subjects who are currently pregnant or lactating * Positive pregnancy test * Use of tobacco or nicotine products within 3 months prior to Screening * Significant alcohol consumption * History of drug abuse within the previous 2 years, or a positive drug screen * History of allergy to study medications * Undergoing abrupt discontinuation of alcohol or sedatives * Not suitable for study in the opinion of the Principal Investigator

Locations (1)

Syneos Health Clinical Research Services, LLC.

Miami, Florida, United States